Weekly Top News – Psoriasis – July 6, 2020

July 6, 2020

Skyrizi (risankizumab) / AbbVie, Boehringer Ingelheim
Study of Subcutaneous Risankizumab Injection to Assess Change in Palmoplantar Pustulosis Area and Severity Index [PPPASI] in Adult Japanese Participants With Palmoplantar Pustulosis (clinicaltrials.gov) – Jun 30, 2020 – P3; N=116; Not yet recruiting; Sponsor: AbbVie

 

Siliq (brodalumab) / Bausch Health, LEO Pharma, Kyowa Hakko Kirin
Efficacy and safety of brodalumab in adolescents from 12 to 17 years of age with moderate-to-severe plaque psoriasis (clinicaltrialsregister.eu) – Jun 30, 2020 – P3; N=120; Sponsor: LEO Pharma A/S

 

Ilumya (tildrakizumab-asmn) / Sun Pharma, Almirall
Sun Pharmaceutical Industries receives Japan MHLW approval for Ilumya (Business Standard) – Jun 29, 2020 – “Sun Pharmaceutical Industries announced that one of its wholly-owned subsidiaries has received approval from the Ministry of Health, Labour and Welfare (MHLW), Japan for Ilumya (tildrakizumab) for the treatment of plaque psoriasis in adult patients who have an inadequate response to conventional therapies.”

 

AVT02 (adalimumab biosimilar) / Cipla, Alvotech
Pharmacokinetic, Efficacy, Safety, and Immunogenicity of AVT02 With Moderate to Severe Chronic Plaque Psoriasis (clinicaltrials.gov) – Jul 1, 2020 – P3; N=448; Not yet recruiting; Sponsor: Alvotech Swiss AG

 

bimekizumab (UCB4940) / UCB; Humira (adalimumab) / Eisai, AbbVie
BE OPTIMAL: A Study to Test the Efficacy and Safety of Bimekizumab in the Treatment of Subjects With Active Psoriatic Arthritis (clinicaltrials.gov) – Jul 1, 2020 – P3; N=840; Recruiting; Sponsor: UCB Biopharma SRL; Suspended –> Recruiting

 

bimekizumab (UCB4940) / UCB
BE COMPLETE: A Study to Evaluate the Efficacy and Safety of Bimekizumab in the Treatment of Subjects With Active Psoriatic Arthritis (clinicaltrials.gov) – Jul 1, 2020 – P3; N=390; Recruiting; Sponsor: UCB Biopharma S.P.R.L.; Suspended –> Recruiting

No Comments

Post a Comment

Comment
Name
Email
Website